Progen completes PG545 second patient cohort assessment
THE ROADHOUSE PHARMACY: Progen Pharmaceuticals (ASX: PGL) has completed assessment of the second patient cohort in the company’s PG545 Phase 1 clinical trial. Progen said it had, in conjunction with with an independent medical monitor and the co-ordinating investigators, reviewed the safety data from this cohort and all involved have agreed to progress to the […]




